Navigation Links
Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
Date:11/24/2008

ear efficacy in this difficult type of osteoarthritis patients and showing the same GI adverse event rate as placebo. The blood pressure data are consistent with previous studies and we are keenly awaiting the important results of the pre-defined statistical analysis in the next few weeks, following the pooling of the 301, 302 and 303 blood pressure data. We are confident that these results will clearly demonstrate naproxcinod's non-detrimental blood pressure profile, in contrast to naproxen."

Design and results of the 303 study

The 303 study was a 13-week, double-blind, placebo and naproxen controlled trial in patients with OA of the hip. 810 patients were enrolled at 120 clinical centers in the United States, Canada and Europe. Eligible patients had a diagnosis of primary osteoarthritis of the hip of at least three months in duration and were randomized on a 2:2:1 basis to receive naproxcinod 750 mg bid, placebo bid and naproxen 500 mg bid, respectively.

The three co-primary endpoints of the study compared the efficacy of naproxcinod 750 mg bid to placebo, in terms of the mean change between baseline and week 13 in the following scores: the WOMAC(TM) pain subscale, the WOMAC(TM) function subscale and the subject's overall rating of disease status. The results demonstrated that naproxcinod was superior to placebo with high statistical significance (p<0.001) on all three of these co-primary endpoints. These were the same endpoints as those used in the 301 and 302 phase 3 studies. No statistical comparison was made between naproxen 500 mg bid and the other two arms on the efficacy endpoints, due to the 2:2:1 randomization in the study, although numerical data show that naproxcinod 750 mg bid behaved in a similar fashion to naproxen 500 mg bid on these efficacy scores. NicOx entered into a full-service agreement for the conduct of the 303 study with Covance Inc., a global contract research organizati
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

13611

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
2. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
3. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
4. CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011-vcMMAE Phase II Trial Results on November 3, 2008
5. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
6. Physicians Estimate That if Approved, Ceftobiprole Will Steal Nearly a Third of Zyvoxs Patient Share in the Treatment of Nosocomial Pneumonia
7. NewCardio Announces Positive Results From Third Clinical Validation Study
8. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
9. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
10. NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit
11. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Full Service CRO ... the new Vice President of Business Development. Peter has ... in a number of different business development positions with ... positions were primarily related to business development/sales management and ... 30 years makes him a key and strategic asset ...
(Date:7/25/2014)... MARLTON, N.J. , July 25, 2014 /PRNewswire/ ... visibility, brand protection and serialization solutions, has recently ... Business" that addresses current and future needs ... solutions for the old supply chain model no ... advances in technology, including the growth of mobile ...
(Date:7/25/2014)... 25, 2014  IDEXX Laboratories, Inc. (NASDAQ: ... quarter of 2014 increased 11% versus the prior year ... for the second quarter of 2014 versus the prior ... in distributor inventory 2 . Earnings per diluted share ... 11% from the prior year period to $1.10."In the ...
Breaking Medicine Technology:Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2Acsis Addresses Questions on the Modern Supply Chain 2IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29IDEXX Laboratories Announces Second Quarter Results 30IDEXX Laboratories Announces Second Quarter Results 31IDEXX Laboratories Announces Second Quarter Results 32IDEXX Laboratories Announces Second Quarter Results 33IDEXX Laboratories Announces Second Quarter Results 34
... 2010 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: ... fast-growing, profitable developer, manufacturer and seller of medicine and ... today that the Company will effect a two-for-one reverse ... minimum share price requirements in connection with its application ...
... 31, 2010 CVS Caremark (NYSE: CVS ... to acquire the Medicare Part D business of Universal ... billion.  Universal American is a leading Medicare Prescription Drug Plan ... acquisition will more than double the size of CVS ...
Cached Medicine Technology:Lotus Pharmaceuticals Announces Approval of Reverse Stock Split 2CVS CAREMARK to Purchase Universal American's Medicare Part D Business 2CVS CAREMARK to Purchase Universal American's Medicare Part D Business 3CVS CAREMARK to Purchase Universal American's Medicare Part D Business 4
(Date:7/26/2014)... As reported by Lauren Hunter of ... 3 factors: smaller spaces, multi-generational access, and water consumption. ... 2014 lists, including this article on Freshome , ... a leading manufacturer of steam bath generators, has noticed ... smaller spaces and an effort to reduce water consumption. ...
(Date:7/26/2014)... 26, 2014 As reported in ... 23rd, new research by Palo Alto Networks shows that ... playbook, now focusing more on businesses and their digital ... become increasingly wise to their tactics over the years. ... Joe Caruso, talks about the evolution of 419 scams ...
(Date:7/26/2014)... “Healthy teeth are important, and having your teeth cleaned regularly ... Health Center of Snohomish County (CHC) in their article, “ ... integration of medical and dental care is the best way ... encourage regular cleanings and checkups not only with a family ... adults will find knowledgeable and friendly staff that ...
(Date:7/26/2014)... July 26, 2014 Multiple sclerosis ... disseminata, is an inflammatory disease in which the ... and spinal cord are damaged. This damage disrupts ... to communicate, resulting in a wide range of ... psychiatric problems. Multiple sclerosis takes several forms, with ...
(Date:7/26/2014)... (PRWEB) July 26, 2014 The U.S. Food ... list that includes a new medication guide for AndroGel to ... serious side-effect of taking the topical low testosterone medication, notes ... AbbVie Inc., the makers of the low testosterone theapy drug, ... of pain, swelling or redness as signs of a blood ...
Breaking Medicine News(10 mins):Health News:Amerec Finds Bathroom Design Trends Change Based on Water Consumption and Other Factors 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 3Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 4Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 5Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 6Health News:Common Dental Care Questions Answered by Community Health Center of Snohomish County in Recent Article 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 3Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5
... A residential summer weight-loss camp markedly improved obese ... Pediatrics reports. A Saint Louis University ... index (BMI), physical fitness and blood pressure. "Weight ... the social environment to be successful," said Nadim Kanafani, ...
... diabetes may be related to trend toward less sleep, ... Adding to the many reasons why people should get adequate ... cause insulin resistance, a component of type 2 diabetes. , ... measured after a night of normal sleep (about eight hours) ...
... levels increased more than 50% after timing change, researchers say ... make better use of a vitamin D supplement if you ... Researchers at the Cleveland Clinic examined 17 patients with vitamin ... period of two to three months, the patients were told ...
... May 2010 -- An international team of researchers has ... with HER2 over-expressing breast cancer do not respond to ... research, presented at the IMPAKT Breast Cancer Conference in ... clinical trial design and treatment strategies in HER2 over-expressing ...
... to 10 million women take hormone therapies, which are ... hormones lost from inactive ovaries. Progestin is a hormone ... of estrogen therapy on the uterus. In studies sponsored ... found that estrogen and progestin in hormone therapies increase ...
... ... held liable of confirmation fraud if an employee responds falsely to a confirmation request. ... requests, new guidance from the standards-setting boards supporting the use of secure electronic confirmations now ... ...
Cached Medicine News:Health News:The biggest winners: Summer campers 2Health News:One Sleepless Night Ups Insulin Resistance 2Health News:Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies 2Health News:Breast cancer metastasis increases after estrogen and progestin hormone therapies, MU study finds 2Health News:Brian Fox to Speak on Audit Confirmation Fraud at the 2010 IAPP Annual Forum and Expo 2
... Mono-M Test is a qualitative enzyme ... to Paul-Bunnell heterophil, Epstein-Barr virus capsid ... used in conjunction with Mono-G Test, ... serodiagnosis of infectious (EBV) mononucleosis and ...
... The ImmunoWELL VCA IgM Test is an ELISA ... to Epstein-Barr Virus viral capsid antigen (VCA) in ... used in conjunction with other testing such as ... EBV early antigen tests and/or heterophile tests, the ...
The ImmunoWELL Borrelia (Lyme) Test is an enzyme immunoassay (EIA) for the qualitative and/or semiquantitative detection of Borrelia burgdorferi total antibodies (IgG, IgM, and IgA) in serum and is u...
... ImmunoDOT is dot-blot assay system combining ... microwell, a purified antigen set at a ... membrane. Reactivity is detected using the same ... assays., ,ENA/DNA combines antigens detected in Auto ...
Medicine Products: